PAP
LXEO icon

Persistent Asset Partners’s Lexeo Therapeutics LXEO Stock Holding History

Persistent Asset Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,025
Closed -$159K – 419
2025
Q4 		$159K Buy
+16,025
New +$146K 0.07% 238

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Persistent Asset Partners's LXEO Position: Q1 2026 in Review

Persistent Asset Partners sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 16,025 shares — an estimated $159K sold.

Persistent Asset Partners first reported a position in LXEO in Q4 2025 and held it in 1 quarter. The position peaked at $159K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Persistent Asset Partners reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 16,025 Lexeo Therapeutics shares in Q1 2026, an estimated $159K.
  • Persistent Asset Partners first reported a position in Lexeo Therapeutics in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Lexeo Therapeutics position peaked at $159K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.